Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02056015 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02056015 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT02056015, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is a first-in-human (FIH), single-dose, open-label, phase 1 study designed to assess the safety, pharmacokinetics (PK), distribution, and radiation dosimetry of \[68Ga\]MLN6907 after a single intravenous (IV) administration. Patients with Metastatic Colorectal Carcinoma who are scheduled for resection of liver metastases as part of their treatment plan will be eligible for enrollment.
Interventions
- DRUG [68Ga]MLN6907
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02056015
The ClinicalTrials.gov registry entry for NCT02056015 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [68Ga]MLN6907 is the first listed.
NCT02056015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02056015 about?
NCT02056015 is a clinical study titled "A Phase I Study of MLN6907 in Patients With Metastatic Colorectal". This study is a first-in-human (FIH), single-dose, open-label, phase 1 study designed to assess the safety, pharmacokinetics (PK), distribution, and radiation dosimetry of \[68Ga\]MLN6907 after a single intravenous (IV) administration. Patients with Metastatic Colorectal Carcinoma who are scheduled ...
What is the current status of trial NCT02056015?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02056015?
The interventions under investigation include: [68Ga]MLN6907 (DRUG).
Who is sponsoring clinical trial NCT02056015?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.